# Romidepsin Versus Combination of Romidepsin Plus Pralatrexate in PTCL

> **NCT03355768** · PHASE3 · WITHDRAWN · sponsor: **Jennifer Amengual**

## Conditions studied

- Lymphoma, T-Cell, Peripheral

## Interventions

- **DRUG:** Romidepsin
- **DRUG:** Pralatrexate

## Key facts

- **NCT ID:** NCT03355768
- **Lead sponsor:** Jennifer Amengual
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2018-09-01
- **Primary completion:** 2018-11-01
- **Final completion:** 2018-11-01
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Study was never opened due to lack of funding
- **Last updated:** 2018-12-19

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03355768

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03355768, "Romidepsin Versus Combination of Romidepsin Plus Pralatrexate in PTCL". Retrieved via AI Analytics 2026-05-23 from https://api.ai-analytics.org/clinical/NCT03355768. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*